Trial intelligence / Profile preview

Bimekizumab vs risankizumab in adults with active psoriatic arthritis

2024-511738-11-00Phase 3Completed

Sponsor: UCB
Start: Nov 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 11

Overview

Phase 3, randomised, double-blind trial of bimekizumab in psoriatic arthritis (PsA) and psoriasis (3 arms), sponsored by UCB. Primary endpoint: American College of Rheumatology 50 (ACR50) response at Week 16. Started Nov 2024; status: completed.

Drugs

bimekizumab

Conditions

psoriatic arthritis (PsA)psoriasis

Beyond the preview

Go deeper on 2024-511738-11-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-511738-11-00.